ERBB2 and breast carcinoma: Consistent with the literature, we found that from all of the cancer sub-tissues, breast cancer contributed the most to the Sen-Scoreglobal of ErBb2, as high ErbB2 expression was significantly associated with sensitivity to 62% of the drugs in the ErbBs sign.